This study will investigate the GH secretory activity and selectivity of two doses of MK-0677 in healthy older subjects. There will be two 14 day treatment periods, as well as a third 14 day extension period of treatment for collection of safety data. It will determine whether multiple doses of MK-0677 will be sufficiently safe and well-tolerated to support continued clinical investigation in elderly populations.
Showing the most recent 10 out of 674 publications